Loading...
•
Jun 30, 2025
Gyre Therapeutics Q2 2025 Earnings Report
Key Takeaways
Gyre Therapeutics posted Q2 2025 revenue of $26.8 million and net income of $1.6 million. Earnings were supported by the successful launch of Etorel and continued rollout of Contiva in the PRC. Operating income declined year-over-year due to higher marketing and administrative costs.
Revenue reached $26.8 million, up from $25.2 million a year ago, due to new product launches.
Net income fell to $1.6 million from $4.5 million in Q2 2024 due to increased operating expenses.
Cash, short-term deposits, and CDs totaled $75.9 million at quarter-end.
Sales in the PRC were driven by Etuary ($23.5M), Etorel ($1.6M), and Contiva ($1.5M).
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Gyre anticipates revenue growth for the remainder of 2025 driven by continued product launches in the PRC and expansion into new indications.
Positive Outlook
- Projected full-year 2025 revenue of $118–128 million.
- Phase 3 success of Hydronidone supports future filings in PRC.
- Ongoing U.S. expansion with Phase 2 trial of Hydronidone for MASH expected in 2H 2025.
- Launch of Etorel and Contiva is contributing to commercial momentum.
- Strong cash reserves support R&D and commercialization plans.
Challenges Ahead
- Net income declined year-over-year due to higher operating costs.
- Income from operations decreased by $1.0 million vs. Q2 2024.
- G&A expenses rose by $1.4 million from prior year.
- Continued reliance on PRC market for all reported revenue.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...